Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 775 of 2026 entries
View as:

A Study of the Effect of RO4917838 on Biomarker Measures of Cognitive Dysfunction in Participants With Schizophrenia and Schizoaffective Disorder

Phase: N/A Priority: Normal
NCT ID: NCT01116830 Org: User:
Start: 11/30/10 End: 02/28/14 Due: 02/28/15

A Dose-finding Study of RO5323441 in Patients With Metastatic Treatment-Refractory Colorectal or Ovarian Cancer

Phase: N/A Priority: Normal
NCT ID: NCT01148758 Org: User:
Start: 05/31/10 End: 09/30/10 Due: 09/30/11

A Non-interventional Functional Magnetic Resonance Imaging (fMRI) Study and Behavioral Assessment in Healthy Participants

Phase: N/A Priority: Normal
NCT ID: NCT02560142 Org: User:
Start: 08/31/15 End: 02/29/16 Due: 02/28/17

An Extension Study of Tocilizumab (Myeloma Receptor Antibody [MRA]) in Patients Completing Treatment in Tocilizumab Core Studies

Phase: N/A Priority: Normal
NCT ID: NCT00720798 Org: User:
Start: 09/30/05 End: 04/30/13 Due: 04/30/14

An Observational Study to Evaluate the Effectiveness of Mircera Treatment for Renal Anemia in Pre-dialysis Participants With Chronic Kideny Disease (CKD)

Phase: N/A Priority: Normal
NCT ID: NCT02547454 Org: User:
Start: 12/31/08 End: 11/30/14 Due: 11/30/15

A Study of Xeloda (Capecitabine) in Combination With Oxaliplatin in Patients With Metastatic Colorectal Cancer.

Phase: N/A Priority: Normal
NCT ID: NCT00353262 Org: User:
Start: 07/31/05 End: 04/30/08 Due: 04/30/09

A Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study

Phase: N/A Priority: Normal
NCT ID: NCT03768063 Org: User:
Start: 02/28/19 End: 07/05/28 Due: 07/05/29

A Study of Avastin (Bevacizumab) in Combination With Herceptin (Trastuzumab) and Xeloda (Capecitabine) in Patients With HER2-Positive Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00811135 Org: User:
Start: 12/31/08 End: 12/31/15 Due: 12/31/16

A Study of Aleglitazar in Patients With Type 2 Diabetes

Phase: N/A Priority: Normal
NCT ID: NCT00388518 Org: User:
Start: 11/30/06 End: 03/31/08 Due: 03/31/09

A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Combination With Ribavirin in Patients With Chronic Hepatitis C (CHC) Previously Treated With PEG-Intron + Ribavirin

Phase: N/A Priority: Normal
NCT ID: NCT00087568 Org: User:
Start: 01/31/03 End: 03/31/06 Due: 03/31/07

A Study of Balapiravir in Patients With Dengue Virus Infection

Phase: N/A Priority: Normal
NCT ID: NCT01096576 Org: User:
Start: 07/31/10 End: 04/30/11 Due: 04/30/12

A Study To Assess the Quality and Strength of Bone in Women Participants With Osteoporosis Taking Oral Ibandronate Versus Placebo

Phase: N/A Priority: Normal
NCT ID: NCT00148915 Org: User:
Start: 08/31/05 End: 08/31/07 Due: 08/31/08

A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Neovascular Age-Related Macular Degeneration (LUCERNE)

Phase: N/A Priority: Normal
NCT ID: NCT03823300 Org: User:
Start: 03/11/19 End: 01/07/22 Due: 01/07/23

A Study Evaluating the Safety and Pharmacokinetics of Atezolizumab Administered in Combination With Hu5F9-G4 to Patients With Relapsed and/or Refractory Acute Myeloid Leukemia

Phase: N/A Priority: Normal
NCT ID: NCT03922477 Org: User:
Start: 10/08/19 End: 11/03/20 Due: 11/03/21

CLL11: A Study of Obinutuzumab (RO5072759 [GA101]) With Chlorambucil in Patients With Previously Untreated Chronic Lymphocytic Leukemia (Stage 2)

Phase: N/A Priority: Normal
NCT ID: NCT02053610 Org: User:
Start: 12/31/09 End: 08/23/17 Due: 08/23/18

A Study of Oral Vismodegib for the Treatment of Idiopathic Pulmonary Fibrosis (IPF)

Phase: N/A Priority: Normal
NCT ID: NCT02168530 Org: User:
Start: 10/31/14 End: 01/31/17 Due: 01/31/18

A Study to Collect Blood Samples From Patients With Spinal Muscular Atrophy for Biomarker Analysis

Phase: N/A Priority: Normal
NCT ID: NCT01910168 Org: User:
Start: 08/31/13 End: 02/28/14 Due: 02/28/15

A Study in Participants Previously Enrolled in a Genentech- and/or F. Hoffmann-La Roche Ltd-Sponsored Atezolizumab Study (IMbrella A)

Phase: N/A Priority: Normal
NCT ID: NCT03148418 Org: User:
Start: 09/20/17 End: 03/06/30 Due: 03/06/31

Dose Finding Study Of CP-870,893, An Immune System Stimulating Antibody, In Combination With Paclitaxel And Carboplatin For Patients With Metastatic Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT00607048 Org: User:
Start: 11/30/07 End: 07/31/09 Due: 07/31/10

A Study of The Effects of Multiple Doses of Ketoconazole on Single Dose Pharmacokinetics of RO4602522 in Healthy Male Volunteers

Phase: N/A Priority: Normal
NCT ID: NCT01625806 Org: User:
Start: 07/31/12 End: 12/31/12 Due: 12/31/13

A Study to Evaluate the Efficacy and Safety of Faricimab in Patients With Choroidal Neovascularization Secondary to Pathologic Myopia

Phase: N/A Priority: Normal
NCT ID: NCT06176352 Org: User:
Start: 03/06/24 End: 04/21/26 Due: 04/21/27

A Study of Avastin (Bevacizumab) in Patients With Non-Squamous Non-Small Cell Lung Cancer With Asymptomatic Untreated Brain Metastasis

Phase: N/A Priority: Normal
NCT ID: NCT00800202 Org: User:
Start: 04/30/09 End: 10/31/12 Due: 10/31/13

A Study of Cardiac Safety in Patients With HER2 Positive Early Breast Cancer Treated With Herceptin

Phase: N/A Priority: Normal
NCT ID: NCT01152606 Org: User:
Start: 08/30/07 End: 05/31/16 Due: 05/31/17

Study Of Entrectinib (Rxdx-101) in Children and Adolescents With Locally Advanced Or Metastatic Solid Or Primary CNS Tumors And/Or Who Have No Satisfactory Treatment Options

Phase: N/A Priority: Normal
NCT ID: NCT02650401 Org: User:
Start: 05/03/16 End: 06/30/26 Due: 06/30/27

A Study of Vemurafenib (RO5185426) in Comparison With Dacarbazine in Previously Untreated Patients With Metastatic Melanoma (BRIM 3)

Phase: N/A Priority: Normal
NCT ID: NCT01006980 Org: User:
Start: 01/31/10 End: 07/31/15 Due: 07/31/16